作者
Mahshid Saleh, Amir Abbas Vaezi, Rasoul Aliannejad, Amir Ali Sohrabpour, Seyedeh Zahra Fotook Kiaei, Mahdi Shadnoush, Vahid Siavashi, Leila Aghaghazvini, Batoul Khoundabi, Shahriyar Abdoli, Bahram Chahardouli, Iman Seyhoun, Neda Alijani, Javad Verdi
发表日期
2021/12
期刊
Stem cell research & therapy
卷号
12
页码范围
1-13
出版商
BioMed Central
简介
Background
Mesenchymal stem cells (MSCs) have received particular attention because of their ability to modulate the immune system and inhibit inflammation caused by cytokine storms due to SARS-CoV-2. New alternative therapies may reduce mortality rates in patients with COVID19. This study aimed to assess the safety and efficacy of injecting intravenous Wharton’s jelly-derived MSCs in patients with COVID-19 as a treatment.
Methods
In this study, five patients with severe COVID-19 were treated with Wharton’s jelly-derived mesenchymal stem cells (150 × 106 cells per injection). These patients were subject to three intravenous injections 3 days apart, and monitoring was done on days 0, 3, 6, and 14 in routine tests, inflammatory cytokines, and flow cytometry of CD4 and CD8 markers. A lung CT scan was performed on base and days 14 and 28. In …
学术搜索中的文章
M Saleh, AA Vaezi, R Aliannejad, AA Sohrabpour… - Stem cell research & therapy, 2021